Amylyx Pharmaceuticals (AMLX) Receivables - Net (2022 - 2025)

Amylyx Pharmaceuticals has reported Receivables - Net for 4 years, with the latest figure at $88000.0 in Q4 2025.

• On a quarterly basis, Receivables - Net fell 80.31% year-over-year to $88000.0 in Q4 2025; TTM through Dec 2025 was $88000.0, a 80.31% decrease from a year earlier, with the FY2025 full-year figure at $88000.0, down 80.31% from the prior year.
• Receivables - Net was $88000.0 for Q4 2025 at Amylyx Pharmaceuticals, down from $132000.0 in the prior quarter.
• The five-year high for Receivables - Net was $40.0 million in Q4 2023, with the low at $88000.0 in Q4 2025.
• Average Receivables - Net over 4 years is $11.7 million, with a median of $2.9 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Receivables - Net jumped 21325.55% in 2023, then tumbled 98.88% in 2024.
• Over 4 years, Receivables - Net stood at $15.3 million in 2022, then soared by 161.66% to $40.0 million in 2023, then sank by 98.88% to $447000.0 in 2024, then tumbled by 80.31% to $88000.0 in 2025.
• The last three Receivables - Net figures came in at $88000.0 (Q4 2025), $132000.0 (Q3 2025), and $103000.0 (Q2 2025), per Business Quant data.